VistaSeq® RET Comprehensive Analysis
Also known as: Familial Cancer testing, Hereditary Cancer testing, Inherited Cancer testing, Medullary Thyroid Cancer (MTC), MEN2
Use
This assay is intended for patients with a history consistent with Multiple Endocrine Neoplasia, type 2.
Special Instructions
Not provided.
Limitations
The VistaSeq® RET analysis is unable to detect variants in noncoding or deep intronic regions, and may not reliably detect microsatellite repeats, mosaic variants, or genomic rearrangements such as transposable elements or inversions. Copy number analysis could miss some partial exon rearrangements and the presence of pseudogenes might affect the detection of variants in specific genes. The assay is not intended for detecting somatic mutations, and bone marrow transplants might impact outcomes. Interpretations should be clinically correlated considering potential interactions of variants across different genes and hereditary syndrome causes not covered by this test.
Methodology
NGS (Targeted)
Biomarkers
RET
Gene
LOINC Codes
- 21734-9 - RET gene Mut Tested Bld/T
- 31208-2 - Specimen source
- 56850-1 - Imp & review of lab results
- 62385-0 - Recommendation Patient Doc-Imp
- 42349-1
- 49549-9 - Ref lab test method
- 75608-0 - Citation Ref Lab Test
- 72486-4 - Lab director name Provider
- 11502-2 - Laboratory report
Result Turnaround Time
20-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
7 mL
Container
Lavender-top (EDTA) tube or yellow-top (ACD) tube
Collection Instructions
Blood is collected by routine phlebotomy.
Storage Instructions
Room temperature or refrigerated
Causes for Rejection
Frozen specimen; leaking tube; clotted specimen; grossly or hemolyzed specimen; quantity not sufficient for analysis; incorrect anticoagulant.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 60 days |
| Refrigerated | 60 days |
| Frozen | N/A |
Other tests from different labs that may be relevant